skip to main content
UK Health Security Agency

RPMI 1788

RPMI 1788

Catalogue No.

85112106

Cell Line Name

RPMI 1788

Cell Line Description

Derived from the peripheral blood of an apparently normal 33-year-old Caucasian male. The cells secrete IgM (lambda light chain). HLA = A2, Aw33, B7, B14. Cells express the gene for and produce immunoglobulin and Lymphotoxin (LT), also known as Tumour Necrosis Factor beta (TNFβ). EBV (EBNA) genome (also known as Human Herpes Virus 4) is present in very small quantities, based on the number of EBV genome equivalents/cell (detected by RNA-DNA hybridization). Therefore, cells are EBV/EBNA positive.

Characteristics

Products

Immunoglobulin M (IgM) (Lambda light chain)

Tissue of Origin

Blood

DNA profile (STR Profile)

Amelogenin: X,Y
CSF1PO: 10
D5S818: 12,13
D7S820: 10,12
D13S317: 11,13
D16S539: 10,13
TH01: 6,9.3
TPOX: 8,9
vWA: 18,19

Karyotype

2n = 46, modal no. 45

Disease

None Stated

Culture Conditions

Cell Type

Lymphoblastoid

Subculture Routine

Maintain cultures between 3-4x100,000 cells/ml; 5% CO₂; 37°C. Maximum cell density 1-2x1,000,000 cells/ml.

Culture Medium

RPMI 1640 + 2mM Glutamine + 20% Foetal Bovine Serum (FBS).

Growth Mode

Suspension

Additional Info

Depositor

Obtained from ATCC

Country of Origin

United States

Hazard Group (ACDP)

Hazard Group (ACDP) 2

Applications

References

Huang, C.C, Moore, G.E. Chromosomes of 14 hematopoietic cell lines derived from peripheral blood of persons with and without chromosome anomalies. J. Natl. Cancer Inst. 43: 1119-1128, 1969. PubMed: 5353241 Minowada, J., Nonoyama, M., Moore, G.E., Rauch, A.M., and Pagano, J.S. The Presence of the Epstein-Barr Viral Genome in Human Lymphoblastoid B-Cell Lines and its absence in a Myeloma Cell Line. Cancer Res. 34: 1898-1903, 1974. Pubmed: 4366935 Kennedy, G., Kumano, J and Sugden B. Epstein-Barr Virus provides a Survival Factor to Burkitt’s Lymphomas. PNAS. 100 [24]: 14269-14274. 2003. Pubmed: 14603034 Aggarwal, B.B., Moffat, B and Harkins, R.N. Human Lymphotoxin. Production of a Lymphoblastoid Cell Line, Purification and Initial Characterization. J Biol. Chem. 259 [10]: 686-691. 1984. Pubmed: 6608523 Stone-Wolff, D. S., YIP, Y.K., Kelker, H.C., Le, J., Henriksen-Destefano, D., Rubin, B.Y., Rinderknecht, E., Aggarwal, B.B and Vilček, Interrelationships of human Interferon-Gamma with Lymphotoxin and Monocyte Cytotoxin. J. Exp Med 159: 828-843. 1984. Pubmed: 6421983

Available Formats

  • Frozen
  • DNA-5µg (100ng/µl)

If use of this culture results in a scientific publication, it should be cited in the publication as: RPMI 1788 (ECACC 85112106).

Unless specified otherwise, at ECACC we routinely handle all of our cell lines at containment level 2 in accordance with the ACDP guidelines (Advisory Committee on Dangerous Pathogens) (UK). All cell cultures have the potential to carry as yet unidentified adventitious agents. It is the responsibility of the end user to ensure that their facilities comply with biosafety regulations for their own country. ACDP Guidance: Biological agents: Managing the risks in laboratories and healthcare premises.

The Culture Collections represent deposits of cultures from world-wide sources. While every effort is made to ensure details distributed by Culture Collections are accurate, Culture Collections cannot be held responsible for any inaccuracies in the data supplied. References where quoted are mainly attributed to the establishment of the cell culture and not for any specific property of the cell line, therefore further references should be obtained regarding cell culture characteristics. Passage numbers where given act only as a guide and Culture Collections does not guarantee the passage number stated will be the passage number received by the customer.

Cultures supplied by Culture Collections are for research purposes only. Enquiries regarding the commercial use of a cell line are referred to the depositor of the cell line. Some cell lines have additional special release conditions such as the requirement for a material transfer agreement to be completed by the potential recipient prior to the supply of the cell line. Please view the Terms & Conditions of Supply for more information.